Merck & Co., Inc. (NYSE:MRK) is included in our list of the best stocks to buy for financial stability.
On March 25, 2026, Merck & Co., Inc. came into the limelight when Reuters reported that the company had agreed to buy Terns Pharma for $6.7 billion. The move comes as the company looks to expand its cancer pipeline amid concerns surrounding the looming patent loss for blockbuster therapy Keytruda.
By the end of this decade, Merck & Co., Inc. is expected to lose patent protection for the therapy.
The move is part of Merck’s threefold expansion of its late-stage pipeline since 2021, which is supported by in-house development and major deals. Previously, the company acquired Acceleron, gaining access to the pulmonary arterial hypertension drug Winrevair for $11.5 billion.
The transaction represents a 6% premium to the stock’s last close, settling at $53 per share. Following the announcement, a 5.5% share price gain was noted by the end of the day’s session.
The deal provides Merck & Co., Inc. with access to Terns Pharma’s TERN-701, an experimental drug being tested as a treatment for chronic myeloid leukemia. The deal is expected to close by Q2 2026.
Merck & Co., Inc., a healthcare company, provides health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
